Monopar (MNPR) Raises ~$91.9M via $67.67 Equity Offer; CEO-Linked Repurchase

Rhea-AI Filing Summary

Monopar Therapeutics entered into an underwriting agreement to sell 1,034,433 shares of common stock at $67.67 per share and pre-funded warrants to purchase 960,542 shares at $67.669 per pre-funded warrant, with immediate exercisability and ownership caps tied to a 9.99% threshold (adjustable to 19.99% with notice). The offering is being made from a shelf registration declared effective September 9, 2025, and is expected to close on September 25, 2025. The company also agreed to repurchase 550,229 shares from existing significant stockholder Tactic Pharma at $63.6098 per share; Chandler D. Robinson, the CEO, is a managing member of Tactic Pharma. After giving effect to the repurchase, net proceeds are expected to be approximately $91.9 million, before estimated offering expenses. A peer-reviewed letter about the company’s investigational therapy ALXN1840 was published in the Journal of Hepatology and disclosed via press release.

Positive

• Substantial capital raise: expected net proceeds of approximately $91.9 million before expenses
• High offering price: public offering price set at $67.67 per share and pre-funded warrant price at $67.669
• Immediate exercisability: Pre-Funded Warrants are exercisable immediately, providing conversion flexibility to investors
• Regulatory clearance: Offering made from a shelf registration declared effective by the SEC on September 9, 2025
• Scientific disclosure: Peer-reviewed letter about ALXN1840 published in the Journal of Hepatology, disclosed via press release

Negative

• Related-party transaction: Share repurchase is from Tactic Pharma, of which CEO Chandler D. Robinson is a managing member
• Repurchase conditioned on offering: The Share Repurchase will only occur if the Offering closes, creating conditionality for the transaction

Insights

Financial Analyst

TL;DR: $91.9M gross financing via high-priced equity and pre-funded warrants supports liquidity; immediate warrant exercisability limits execution risk.

The transaction provides Monopar with material near-term capital, with the combined issuance of shares and pre-funded warrants priced at $67.67 and $67.669 respectively. The expected net proceeds of approximately $91.9 million (after the repurchase but before offering expenses) are sizable relative to typical clinical-stage funding needs and should extend the company’s operating runway. Immediate exercisability of pre-funded warrants simplifies conversion timing for investors, while the ownership caps (9.99% default, up to 19.99% with notice) limit concentration risk. The closing timing (expected September 25, 2025) and standard underwriting terms are consistent with typical follow-on offerings.

Corporate Governance Expert

TL;DR: The repurchase from a related significant stockholder where the CEO is a managing member raises governance disclosure importance but is disclosed.

The Share Purchase Agreement shows the company will repurchase 550,229 shares from Tactic Pharma at $63.6098 per share, conditioned on the closing of the offering. Chandler D. Robinson’s role as a managing member of Tactic Pharma is explicitly disclosed, which is appropriate for transparency. The arrangement and conditioning on the offering are material facts that investors should note; the filing references customary representations and warrants but does not provide additional governance safeguards or independent valuation commentary within the text provided.

8-K Event Classification

3 items: 1.01, 7.01, 9.01

3 items

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is Monopar Therapeutics (MNPR) offering and at what price?

Monopar is selling 1,034,433 shares of common stock at $67.67 per share and pre-funded warrants to purchase 960,542 shares at $67.669 per warrant.

How much net proceeds will MNPR receive from the offering?

After giving effect to the share repurchase and deducting underwriting discounts and commissions (but before estimated offering expenses), net proceeds are expected to be approximately $91.9 million.

What are the terms of the pre-funded warrants in MNPR’s offering?

Each Pre-Funded Warrant is exercisable immediately and has an exercise-price of $0.001 per share; holders face an ownership cap of 9.99% post-exercise (adjustable to 19.99% with notice).

What is the share repurchase with Tactic Pharma?

The company agreed to repurchase 550,229 shares from Tactic Pharma at $63.6098 per share; the repurchase is conditioned on the closing of the Offering.

Is there any related-party involvement disclosed in the filing?

Yes. Chandler D. Robinson, Monopar’s CEO and board member, is a managing member of Tactic Pharma, the counterparty to the Share Purchase Agreement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/24/2025 - 05:06 PM Learn about SEC filing dates

false 0001645469 0001645469 2025-09-23 2025-09-23

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 23, 2025

MONOPAR THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

Delaware		001-39070		32-0463781
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

1000 Skokie Blvd., Suite 350, Wilmette, IL		60091
(Address of principal executive offices)		(Zip Code)

(847) 388-0349

Registrant’s telephone number, including area code

N/A

(Former name or former address, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		MNPR		The Nasdaq Stock Market LLC (Nasdaq Capital Market)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01. Entry into a Material Definitive Agreement.

Underwritten Registered Offering  

On September 23, 2025, Monopar Therapeutics Inc., a Delaware corporation (the “Company” or “Monopar”), entered into an Underwriting Agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC, Leerink Partners LLC and Barclays Capital Inc. (collectively, the “Representatives”), as Representatives of the several underwriters named therein (together with the Representatives, the “Underwriters”), pursuant to which the Company will issue and sell to the Underwriters pursuant to the Underwriting Agreement 1,034,433 shares of Common Stock, par value $0.001 per share (the “Common Stock”), at a public offering price of $67.67 per share, and pre-funded warrants (the “Pre-Funded Warrants”) to purchase 960,542 shares of Common Stock at the purchase price of $67.669 per Pre-Funded Warrant, which represents the public offering price per share for the Common Stock less a $0.001 per share exercise price (the “Offering”).

The Offering is being made pursuant to a shelf registration statement filed August 29, 2025 and declared effective by the Securities and Exchange Commission (the “SEC”) on September 9, 2025 (the “Registration Statement”) (File. No. 333-289947), a base prospectus filed as part thereof, and a prospectus supplement dated September 23, 2025, filed pursuant to Rule 424(b)(5) under the Securities Act of 1933, as amended (the “Securities Act”).

Each Pre-Funded Warrant will be exercisable immediately and may be exercised at any time until exercised in full. A holder (together with its affiliates and other attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise the holder would own more than 9.99% of our outstanding Common Stock immediately after exercise, which percentage may be changed at the holder’s election to a lower or higher percentage not in excess of 19.99% upon 61 days’ notice to us subject to the terms of the Pre-Funded Warrant

The Underwriting Agreement contains customary representations, warranties and agreements by the Company and the Underwriters, customary conditions to closing, and customary indemnification obligations of the Company.

The Company has agreed to provide the Underwriters with customary indemnification and contribution rights, in connection with entering into the Underwriting Agreement.

The opinion of the Company’s counsel regarding the validity of the shares of Common Stock and Pre-Funded Warrants (and shares of Common Stock issuable thereunder) is filed herewith as Exhibit 5.1.

Share Purchase Agreement

On September 24, 2025, the Company entered into a stock purchase agreement (the “Share Purchase Agreement”) with Tactic Pharma, LLC, an existing significant stockholder of the Company (“Tactic Pharma”). Pursuant to the Share Purchase Agreement, the Company agreed to repurchase 550,229 shares of its Common Stock from Tactic Pharma at $63.6098 per share, which is the same price per share as the price at which the shares are being sold to the public in the Offering, less underwriting discounts and commissions (the “Share Repurchase”). Chandler D. Robinson, the Company’s Chief Executive Officer and a member of its board of directors, is a managing member of Tactic Pharma.

The Share Purchase Agreement contains customary representations, warranties and agreements by the Company and Tactic Pharma. The Share Repurchase is conditioned on the closing of the Offering.

The foregoing descriptions of the Underwriting Agreement, the Pre-Funded Warrant, and the Share Purchase Agreement are not complete and are qualified in their entirety by reference to the full text of the Underwriting Agreement, the form of Pre-Funded Warrant, and the Share Purchase Agreement and, copies of which are filed herewith as Exhibits 1.1, 4.1 and 10.1, respectively, and incorporated herein by reference.

Proceeds from Offering

After giving effect to the Share Repurchase, the net proceeds to the Company from the Offering, after deducting underwriting discounts and commissions, but before estimated offering expenses, are expected to be approximately $91.9 million. The Offering is expected to close on September 25, 2025, subject to customary conditions. The Share Repurchase is expected to close promptly thereafter.

Item 7.01. Regulation FD Disclosure

On September 23, 2025, Monopar issued a press release announcing that the Journal of Hepatology had published a peer-reviewed letter to the editor demonstrating rapidly improved copper balance in Wilson disease patients treated with Monopar’s investigational therapy ALXN1840 (tiomolybdate choline).

The press release is furnished as Exhibit 99.1 and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
1.1		Underwriting Agreement, dated September 23, 2025, by and among Monopar Therapeutics Inc., Morgan Stanley & Co. LLC, Leerink Partners LLC, and Barclays Capital Inc.
4.1		Form of Pre-Funded Warrant
5.1		Legal Opinion of Baker & Hostetler LLP
10.1		Share Purchase Agreement, dated September 24, 2025, by and between Monopar Therapeutics Inc. and Tactic Pharma, LLC.
23.1		Consent of Baker & Hostetler LLP (contained in Exhibit 5.1).
99.1		Press Release Dated September 23, 2025.
104		Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Monopar Therapeutics Inc.
Date: September 24, 2025	By:	/s/ Quan Vu
	Name:	Quan Vu
	Title:	Chief Financial Officer